Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in CVS Health Corp (NYSE:CVS) by 1.6% during the first quarter, HoldingsChannel reports. The firm owned 262,737 shares of the pharmacy operator’s stock after buying an additional 4,072 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in CVS Health were worth $15,588,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Banque Cantonale Vaudoise bought a new position in CVS Health during the fourth quarter worth $4,290,000. Bluefin Trading LLC acquired a new position in shares of CVS Health during the fourth quarter valued at about $3,720,000. Alta Capital Management LLC boosted its position in shares of CVS Health by 8.0% during the 4th quarter. Alta Capital Management LLC now owns 539,522 shares of the pharmacy operator’s stock worth $40,081,000 after purchasing an additional 40,161 shares in the last quarter. Stoneridge Investment Partners LLC grew its stake in shares of CVS Health by 33.8% in the 1st quarter. Stoneridge Investment Partners LLC now owns 77,805 shares of the pharmacy operator’s stock valued at $4,616,000 after buying an additional 19,647 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its position in CVS Health by 15.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 1,546,047 shares of the pharmacy operator’s stock valued at $114,531,000 after buying an additional 209,283 shares in the last quarter. Institutional investors own 76.44% of the company’s stock.
Shares of CVS traded down $0.01 on Friday, reaching $63.33. 3,494,416 shares of the company’s stock traded hands, compared to its average volume of 8,148,172. The stock’s 50 day simple moving average is $61.11 and its two-hundred day simple moving average is $67.62. The stock has a market cap of $82.79 billion, a PE ratio of 11.47, a PEG ratio of 1.42 and a beta of 0.73. CVS Health Corp has a 52-week low of $52.04 and a 52-week high of $77.03. The company has a current ratio of 0.99, a quick ratio of 0.70 and a debt-to-equity ratio of 1.29.
CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.28. The firm had revenue of $66.76 billion during the quarter, compared to analyst estimates of $64.11 billion. CVS Health had a return on equity of 15.17% and a net margin of 2.76%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm posted $1.62 EPS. Analysts forecast that CVS Health Corp will post 7.08 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 3.16%. The ex-dividend date of this dividend was Wednesday, April 22nd. CVS Health’s dividend payout ratio is 28.25%.
CVS has been the subject of a number of research reports. UBS Group reduced their price objective on CVS Health from $85.00 to $79.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. JPMorgan Chase & Co. decreased their price target on shares of CVS Health from $97.00 to $94.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Cantor Fitzgerald upped their price objective on shares of CVS Health from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Oppenheimer reiterated a “hold” rating on shares of CVS Health in a report on Wednesday, May 6th. Finally, Deutsche Bank raised their price target on shares of CVS Health from $97.00 to $109.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $80.88.
In related news, SVP James David Clark sold 6,234 shares of CVS Health stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $65.00, for a total value of $405,210.00. Following the sale, the senior vice president now owns 4,817 shares of the company’s stock, valued at approximately $313,105. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Alan Lotvin acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $63.14 per share, for a total transaction of $315,700.00. Following the purchase, the executive vice president now owns 15,161 shares of the company’s stock, valued at approximately $957,265.54. The disclosure for this purchase can be found here. 0.46% of the stock is owned by insiders.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.